Greetings FPC members,
The plot thickens as I present Advaxis, a company with 2 PCa vaccine candidates. The company uses attenuated Listeria monocytogenes, a bacteria, which they utilize to introduce tumor activating antigens (TAA's) to the immune system. This is referred to as their Lm technology or platform--see below:
The first vaccine candidate of interest is ADXS-PSA. The vaccine is being looked at in monotherapy as well as in combination with the CPI, Keytruda for MCRPC. Recently, results were released regarding the KEYNOTE-046 TRIAL-Phase2. and are listed below:
ascopubs.org/doi/abs/10.120...
ir.advaxis.com/news-release...
What makes this particularly interesting is: 1) it increased median survival time in patients with visceral mets, 2) Resulted in stable disease in almost 3/4 of patients, 3) Was useful with Keytruda in patients that were MSI (Micro Satellite Instability) Negative. ISN'T KEYTRUDA SUPPOSED TO WORK ONLY ON MSI HIGH PATIENTS??? (There may be a subset of MSS patients that Keytruda works on, but it is estimated to be small). There is not a Phase 3 trial announced yet or on NCI.
The second candidate of Advaxis is ADSX-504, a part of their HOT program. The HOT program is focused on hotspot mutations-common mutations that drive tumor genes to grow . Using their Lm technology , they seek to develop an "off the shelf" vaccine which does not require genetic testing. The goal being to introduce 30 or so TAA (tumor activating antigens) to present to the immune system. Clearly, the benefit of this would be that this could be administered in the office when diagnosed as a way to begin the fight against PCa. Some info:
advaxis.com/news-releases/n...
pipelinereview.com/index.ph...
This vaccine will likely be focused post BCR with a goal similar to the RV001 vaccine of initiating an immune response that lasts. I imagine the trial will be announced 1st quarter of 2021.
I hope you are enjoying this information so far. The Science is Coming and it gives us HOPE !!! There is more to come....
Don Pescado